Robert Parkinson, Baxter

Chairman and CEO, Baxter International
Total 2014 Compensation: $15.30 million

Baxter ($BAX) chief Robert Parkinson makes a perennial appearance on the list of biopharma's top-paid CEOs, and this year is no exception, despite a slight dip in his overall compensation.

Parkinson netted $15.3 million for 2014, a step down from the $16.2 million he picked up in 2013 and the $17.5 million he pocketed the year before that. While his base salary stayed steady at $1.54 million, and his annual cash bonus shot up 17% to $3.17 million, his stock awards weren't so lucky. Parkinson collected share awards worth $3.6 million, just over half of the $6.8 million he garnered in 2013. Parkinson's pension grew by $2.47 million, and he got options worth $4.54 million.

What Parkinson didn't get--that some of his fellow Baxterites did--was a retention bonus related to the spinoff of the company's biopharma business, Baxalta. The execs leading that charge collected share grants that vest in three years, provided they stick around.

For more:
Special Reports: 15 Highest-Paid Biopharma CEOs of 2013 - Robert Parkinson | 20 Highest-Paid Biopharma CEOs of 2012 - Robert Parkinson - Baxter International
Baxter pays execs more than $8.5M to stick it out through pharma spinoff
Baxter picks HQ for biopharma spinoff, and it's just up the road
Move over, Big Pharma: Smaller biopharma's execs are bringing home more bacon
Meet Baxalta, the pharma spinoff Baxter plans to unleash in 2015

Robert Parkinson, Baxter
Read more on

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.